ArticleJournal of ovarian research2026
ARNTL deregulation promotes ovarian cancer progression and metastasis by activating cancer-associated fibroblasts.
Article in Journal of ovarian research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundCircadian disruption fuels tumor growth, but the role of the core clock gene aryl hydrocarbon receptor nuclear translocator-like (ARNTL) in ovarian cancer is still unclear. We investigated how ARNTL affects ovarian cancer cell proliferation, invasion, and migration, and revealed how it shapes these behaviors by acting on the fibroblast-rich tumor microenvironment.
methodWe engineered SKOV3 cells to either overexpress or silence ARNTL and then measured how fast they migrated, invaded, and proliferated. RNA sequencing (RNA-seq) and pathway analyses were performed, while Microenvironment Cell Populations-counter (MCP-counter) scored fibroblast abundance. In vivo, ovarian cancer cells were subcutaneously inoculated into immunodeficient mice to monitor tumor growth kinetics and quantify proliferative capacity at the organismal level. Single-cell RNA-seq of the tumors and in vitro co-cultures with cancer-associated fibroblasts (CAFs) uncovered how ARNTL re-programs the fibroblast-rich microenvironment to suppress cancer progression.
resultsHere, we found that ARNTL, a circadian core gene, is downregulated in ovarian cancer, and its abundance is negatively correlated with tumor proliferation, invasion, and metastasis. In vitro and in vivo models demonstrated that restoring ARNTL not only inhibits cancer cell proliferation and metastasis, but also reshapes the tumor microenvironment by reducing CAFs recruitment and activation. Mechanistically, ARNTL knockdown promotes PI3K-Akt/TGF-β signaling in ovarian cancer cells and induces CAF activation. Activated CAFs exhibit increased secretion of Stromal Cell-Derived Factor-1 (SDF-1) and Platelet-Derived Growth Factor (PDGF), which reciprocally enhance ovarian cancer cell proliferation and metastatic capacity. Our study indicates that ARNTL functions as a potent tumor suppressor by concurrently repressing cancer cell-intrinsic proliferation-associated genes and reprogramming the phenotype and subset composition of cancer-associated fibroblasts (CAFs) within the tumor microenvironment.
conclusionCollectively, our findings indicate the mechanisms of ARNTL in inhibiting ovarian cancer progression and metastasis via the ARNTL-CAFs axis, and provide a promising strategy for ovarian cancer treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.